we aspire to be the patient-preferred biotech leader.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges.
The figures of the guidance 2022 and 2025 as mentioned below were calculated on the same basis as the actual figures for 2021.
More information closer to the date
€ 5.3 - 5.4 billion
based on continued core product growth and taking into account loss of exclusivity impacts
2022 adj. EBITDA
21% - 22%
reflecting the Zogenix integration, the bimekizumab complete response letter in the US and the macro situation
2022 Core EPS
€ 3.70 - 4.00
based on an average of 189 million shares outstanding
at least € 6 billion
2025 adj. EBITDA
Low- to mid-thirties
2025 Improved ESG
Contact UCB IR Team
firstname.lastname@example.org or a specific team member:
- Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
- Alexander Klein, Investor Relations Lead
Tel: +32 2 559 9948
- Julien Bayet, Investor Relations Lead
Tel: +32 2 559 9580